Literature DB >> 11292629

Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans.

R S Pedersen1, H Bentzen, J N Bech, E B Pedersen.   

Abstract

Arginine vasopressin (AVP) mediates water transport in the renal collecting ducts by forming water channels of aquaporin-2 (AQP2) in the apical plasma membrane. AQP2 is excreted in human urine. We wanted to test the hypothesis that urinary excretion of AQP2 (u-AQP2) reflects the effect of AVP on the renal collecting ducts during water deprivation and hypertonic saline infusion in healthy subjects. Fifteen healthy subjects underwent a 24-h period of fluid restriction. Urine and blood samples were collected at timed intervals. Fifteen healthy subjects were given 7 ml/kg 3% hypertonic saline infusion for 30 min. Urine and blood samples were collected at timed intervals. During fluid restriction, the u-AQP2 rate increased from 3.9 (25th percentile: 3.1; 75th percentile: 5.2) to 7.6 (5.9-9.1; P < 0.001) ng/min, and the plasma AVP (p-AVP) level increased from 0.5 (0.4-0.6) to 3 (1.7-3.3) pmol/l. There was a positive correlation between the maximum change in u-AQP2 rate and the maximum change in p-AVP (r = 0.57, P < 0.03). During the infusion study, u-AQP2 rate was at maximum 90 min after the infusion [baseline: 4.5 ng/min (3.5-4.8); 90 min: 5 ng/min (4.5-6.0) P < 0.02]. p-AVP increased from 1.0 (0.9-1.1) to 1.5 (1.2-1.8; P < 0.002) pmol/l. There was a positive correlation between the maximum change in u-AQP2 rate and the maximum change in p-AVP (r = 0.83; P < 0.0001). It can be concluded that p-AVP and u-AQP2 are increased during thirst and hypertonic saline infusion and that u-AQP2 reflects the action of AVP on the collecting ducts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292629     DOI: 10.1152/ajprenal.2001.280.5.F860

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  28 in total

1.  Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method.

Authors:  Sei Sasaki; Yasukazu Ohmoto; Toyoki Mori; Fusako Iwata; Masahiro Muraguchi
Journal:  Clin Exp Nephrol       Date:  2011-12-10       Impact factor: 2.801

2.  Electrolytes in the aging.

Authors:  Lynn E Schlanger; James L Bailey; Jeff M Sands
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

3.  Markers of the hydration process during fluid volume modification in women with habitual high or low daily fluid intakes.

Authors:  Evan C Johnson; Colleen X Muñoz; Laurent Le Bellego; Alexis Klein; Douglas J Casa; Carl M Maresh; Lawrence E Armstrong
Journal:  Eur J Appl Physiol       Date:  2015-01-07       Impact factor: 3.078

4.  Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  World J Nephrol       Date:  2015-07-06

5.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

6.  Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis.

Authors:  P Ivarsen; J Frøkiaer; N K Aagaard; E F Hansen; F Bendtsen; S Nielsen; H Vilstrup
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

7.  Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.

Authors:  Henrik Vase; Thomas G Lauridsen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study.

Authors:  Erling B Pedersen; Ingrid M Thomsen; Thomas G Lauridsen
Journal:  BMC Nephrol       Date:  2010-10-05       Impact factor: 2.388

9.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

10.  Increased renal sodium absorption by inhibition of prostaglandin synthesis during fasting in healthy man. A possible role of the epithelial sodium channels.

Authors:  Thomas G Lauridsen; Henrik Vase; Jørn Starklint; Carolina C Graffe; Jesper N Bech; Søren Nielsen; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2010-10-28       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.